Dose Insider / Glossary / PIONEER 6

PIONEER 6The heart safety trial of the semaglutide tablet

Updated November 20, 2026 路 3 min read 路 Husain et al., N Engl J Med 2019; RYBELSUS label

PIONEER 6 is the cardiovascular safety trial of oral semaglutide, the daily tablet later sold as Rybelsus. It enrolled 3,183 adults with type 2 diabetes at high cardiovascular risk and gave them oral semaglutide or placebo for a median of 15.9 months. Major cardiovascular events occurred in 3.8% on the tablet against 4.8% on placebo, which met the trial's goal of ruling out harm.

3.8%Major heart events, Oral semaglutide, events over about 16 months
Events over about 16 monthsPIONEER 6, % of patientsMAJOR HEART EVENTSOral semaglutide3.8%Placebo4.8%DEATH FROM ANY CAUSEOral semaglutide1.4%Placebo2.8%Events over about 16 monthsPIONEER 6, % of patientsMAJOR HEART EVENTSOral semaglutide3.8%Placebo4.8%DEATH FROM ANY CAUSEOral semaglutide1.4%Placebo2.8%

Designed to rule out harm; hazard ratio 0.79 for major heart events.

On this page

It was published in the New England Journal of Medicine in 2019.1

How the trial was run

The trial was event-driven, double-blind and placebo-controlled. It enrolled people aged 50 or older with established cardiovascular disease or chronic kidney disease, or aged 60 or older with cardiovascular risk factors only. Its average participant was 66 years old, and 84.7% belonged to the first, higher-risk group.1

The question was safety, not benefit. PIONEER 6 was designed to rule out an 80% excess in cardiovascular risk, with a margin of 1.8 for the upper bound of the hazard ratio.1 That is why it could be short and relatively small. The main outcome was the first of three events: cardiovascular death, non-fatal heart attack or non-fatal stroke. The Rybelsus label identifies the trial by its registry number and says it compared 14 mg of the tablet with placebo.2

What it found

Husain et al., 2019.1

What came next: SOUL

Because PIONEER 6 was built only to rule out harm, a larger trial was needed to test benefit. That trial, SOUL, enrolled 9,650 people with type 2 diabetes and heart disease, kidney disease or both, and gave them the 14 mg tablet or placebo. A first major cardiovascular event occurred in 12% on the tablet against 13.8% on placebo, a hazard ratio of 0.86.2,3 On the strength of these trials, the Rybelsus and Ozempic tablets label includes reducing the risk of major cardiovascular events in adults with type 2 diabetes at high risk of them.2

How to read the result

The drops in cardiovascular death and in death from any cause look large, about half, but they rest on small numbers: 15 against 30 cardiovascular deaths and 23 against 45 deaths from any cause.1 With so few events, chance can move the result a lot, and the trial was not designed to test them. SOUL, larger and longer, is the better guide to how much the tablet protects the heart.

Side effects

Stomach and gut events were the side effects that most often led people to stop the tablet in PIONEER 6.1 In the Rybelsus label's placebo-controlled trials, nausea was reported by 11% on 7 mg and 20% on 14 mg, against 6% on placebo.2 The tablet also has strict rules for taking it: on an empty stomach in the morning with up to 4 ounces of plain water, and nothing else by mouth for 30 minutes. Our page on how to take the Wegovy pill explains why those rules matter for semaglutide tablets.

Limits

The median time in the trial was under 16 months, short for heart outcomes, and the total of 137 major events was small. It was funded by Novo Nordisk, the maker of semaglutide.1

Sources

  1. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes (PIONEER 6). N Engl J Med 2019;381:841-851. Funded by Novo Nordisk; NCT02692716. doi:10.1056/NEJMoa1901118
  2. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, version published August 19, 2026; sections 1, 2, 6.1 and 14. dailymed.nlm.nih.gov
  3. ClinicalTrials.gov record NCT03914326 (SOUL), sponsor Novo Nordisk A/S; read November 20, 2026. clinicaltrials.gov

Related analyses

Log each tablet and the 30-minute wait, and see your mornings on one screen.

Open Dose Insider